ADC Therapeutics S.A.
$1.04
The Read: ADCT’s stock has historically fallen sharply—about 30% after Q2 2026 due to weak ZYNLONTA sales and unclear LOTIS-5 updates, and also declined 4% following Q4 2025 earnings despite strong EPS beats and improved financing.
Price
Overlays
Panel
ADCT
Hover to view data
No Data